Erratum: Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses (Antimicrobial Agents and Chemotherapy (2017) 61:1 (e01305-16) DOI: 10.1128/AAC.01305-16);Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 1, 2017, Pages

  Madelain, Vincent ^a   Guedj, Jeremie ^a   Mentre, France ^a   Nguyen, Thi Huyen Tram ^a   Jacquot, Frederic ^b   Oestereich, Lisa ^c,d   Kadota, Takumi ^e   Yamada, Koichi ^e   Taburet, Anne Marie ^f   De Lamballerie, Xavier ^g,h   Raoul, Herve ^b  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b INSERM   (France)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^d German Center for Infection Research (DZIF)   (Germany)

^e TOYAMA CHEMICAL CO LTD   (Japan)

^f INSERM U1184   (France)

^g Aix Marseille University IRD 190 Inserm 1207   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Favipiravir; Hemorrhagic fever; Modelling; Nonhuman primates; Population pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDEHYDE OXIDASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CHLORINE; CREATINE KINASE; CREATININE; FAVIPIRAVIR; NITROGEN; POTASSIUM; SODIUM; UREA; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ACCOUNTING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARENAVIRUS; ARTICLE; BODY WEIGHT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; DENGUE VIRUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; EBOLAVIRUS; EC50; ENZYME INHIBITION; FEMALE; HEMORRHAGIC FEVER; JUNIN VIRUS; LASSA VIRUS; MACACA FASCICULARIS; MAINTENANCE DRUG DOSE; MALE; MARBURGVIRUS; MATHEMATICAL MODEL; MAURITIAN; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REPEATED DRUG DOSE; RIFT VALLEY FEVER VIRUS; TIME TO TREATMENT; YELLOW FEVER VIRUS; ANIMAL; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; HEMORRHAGIC FEVERS, VIRAL; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATHOGENICITY; VERO CELL LINE; VIROLOGY;

ADMINISTRATION, INTRAVENOUS; ALDEHYDE OXIDASE; AMIDES; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; EBOLAVIRUS; HEMORRHAGIC FEVERS, VIRAL; PRIMATES; PYRAZINES; VERO CELLS;

EID: 85009250147     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02093-17     Document Type: Erratum

References (39)

1. Beeching NJ, Fenech M, Houlihan CF. 2014. Ebola virus disease. BMJ 349:g7348. https://doi.org/10.1136/bmj.g7348.
2. van Paassen J, Bauer MP, Arbous MS, Visser LG, Schmidt-Chanasit J, Schilling S, Ölschläger S, Rieger T, Emmerich P, Schmetz C, van de Berkmortel F, van Hoek B, van Burgel ND, Osterhaus AD, Vossen AC, Günther S, van Dissel JT. 2012. Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever. Lancet Infect Dis 12:635-642. https://doi.org/10.1016/S1473-3099(12)70018-X.
3. Guzman MG, Harris E. 2015. Dengue. Lancet 385:453-465. https://doi.org/10.1016/S0140-6736(14)60572-9.
4. Grant A, Seregin A, Huang C, Kolokoltsova O, Brasier A, Peters C, Paessler S. 2012. Junín virus pathogenesis and virus replication. Viruses 4:2317-2339. https://doi.org/10.3390/v4102317.
5. Ergönül O. 2006. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 6:203-214. https://doi.org/10.1016/S1473-3099(06)70435-2.
6. Ikegami T, Makino S. 2011. The pathogenesis of Rift Valley fever. Viruses 3:493-519. https://doi.org/10.3390/v3050493.
7. Richmond JK, Baglole DJ. 2003. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327:1271-1275. https://doi.org/10.1136/bmj.327.7426.1271.
8. Monath TP, Vasconcelos PFC. 2015. Yellow fever. J Clin Virol 64:160-173. https://doi.org/10.1016/jjcv.2014.08.030.
9. Pigott DC. 2005. Hemorrhagic fever viruses. Crit Care Clin 21:765-783. https://doi.org/10.1016/j.ccc.2005.06.007.
10. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446-454. https://doi.org/10.1016/j.antiviral.2013.09.015.
11. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105:17-21. https://doi.org/10.1016/j.antiviral.2014.02.014.
12. Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krase-mann S, Wurr S, Emmerich P, de Lamballerie X, Ölschläger S, Günther S. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis 8:e2804. https://doi.org/10.1371/journal.pntd.0002804.
13. Oestereich L, Rieger T, Lüdtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Munoz-Fontela C, Günther S. 2016. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis 213:934-938. https://doi.org/10.1093/infdis/jiv522.
14. Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL. 2014. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley fever. PLoS Negl Trop Dis 8:e2790. https://doi.org/10.1371/journal.pntd.0002790.
15. Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H, Gowen BB. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep 5:14775. https://doi.org/10.1038/srep14775.
16. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. 2014. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 104:153-155. https://doi.org/10.1016/j.antiviral.2014.01.012.
17. Gowen BB, Wong M-H, Jung K-H, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. 2007. In vitro and in vivo activities ofT-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51:3168-3176. https://doi.org/10.1128/AAC.00356-07.
18. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 53:202-209. https://doi.org/10.1128/AAC.01074-08.
19. Sissoko D, Laouenan C, Folkesson E, M'Lebing A-B, Beavogui A-H, Baize S, Camara A-M, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala J-L, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah M-C, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart J-M, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, et al. 2016. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 13:e1001967. https://doi.org/10.1371/journal.pmed.1001967.
20. Shurtleff AC, Warren TK, Bavari S. 2011. Nonhuman primates as models for the discovery and development of ebolavirus therapeutics. Expert Opin Drug Discov 6:233-250. https://doi.org/10.1517/17460441.2011.554815.
21. Madelain V, Nguyen THT, Olivo A, de Lamballerie X, Guedj J, Taburet A-M, Mentre F. 2016. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet 55:907-923. https://doi.org/10.1007/s40262-015-0364-1.
22. Lavielle M. 2014. Mixed effects models for the population approach: models, tasks, methods and tools, p 161-197. CRC Press, Boca Raton, FL.
23. Samson A, Lavielle M, Mentre F. 2006. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput Stat Data Anal 51:1562-1574. https://doi.org/10.1016/j.csda.2006.05.007.
24. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143-151. https://doi.org/10.1208/s12248-011-9255-z.
25. Comets E, Brendel K, Mentre F. 2010. Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics. J Soc Fr Statistique 151:106-128.
26. Mentre F, Taburet A-M, Guedj J, Anglaret X, Keita S, de Lamballerie X, Malvy D. 2015. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 15:150-151. https://doi.org/10.1016/S1473-3099(14)71047-3.
27. Obach RS, Huynh P, Allen MC, Beedham C. 2004. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19. https://doi.org/10.1177/0091270003260336.
28. Tosi AJ, Coke CS. 2007. Comparative phylogenetics offer new insights into the biogeographic history of Macaca fascicularis and the origin of the Mauritian macaques. Mol Phylogenet Evol 42:498-504. https://doi.org/10.1016/j.ympev.2006.08.002.
29. Ogawa LM, Vallender EJ. 2014. Genetic substructure in cynomolgus macaques (Macaca fascicularis) on the island of Mauritius. BMC Genomics 15:748. https://doi.org/10.1186/1471-2164-15-748.
30. Pharmaceuticals and Medical Devices Agency. 2014. Review report. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. https://www.pmda.go.jp/files/000210319.pdf.
31. Gowen BB, Sefing EJ, Westover JB, Smee DF, Hagloch J, Furuta Y, Hall JO. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res 121:132-137. https://doi.org/10.1016Zj.antiviral.2015.07.003.
32. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986. https://doi.org/10.1128/AAC.493.981-986.2005.
33. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet A-M. 2010. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 49:17-45. https://doi.org/10.2165/11318110-000000000-00000.
34. Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y. 2009. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother 64:741-746. https://doi.org/10.1093/jac/dkp274.
35. Madelain V, Oestereich L, Graw F, Nguyen THT, de Lamballerie X, Mentré F, Günther S, Guedj J. 2015. Ebola virus dynamics in mice treated with favipiravir. Antiviral Res 123:70-77. https://doi.org/10.1016/j.antiviral.2015.08.015.
36. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508: 402-405. https://doi.org/10.1038/nature13027.
37. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53. https://doi.org/10.1038/nature13777.
38. Takashita E, Ejima M, Ogawa R, Fujisaki S, Neumann G, Furuta Y, Kawaoka Y, Tashiro M, Odagiri T. 2016. Antiviral susceptibility of influenza viruses isolated from patients pre-and post-administration of favipiravir. Antiviral Res 132:170-177. https://doi.org/10.1016/j.antiviral.2016.06.007.
39. Delang L, Segura Guerrero N, Tas A, Quérat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P. 2014. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69: 2770-2784. https://doi.org/10.1093/jac/dku209.